FDA-Approved Breakthrough
Fasikl developed Felix™, the first and only FDA-approved AI therapeutic for essential tremor. This intelligent, non-invasive wristband delivers personalized neuromodulation to address upper-limb functional limitations in adults with essential tremor.
Felix™ was validated in a double-blind, randomized, sham-controlled clinical trial – the highest standard in clinical research. Patients receiving Felix™ experienced highly significant improvements in tremor symptoms compared to the placebo group.
Our core technologies form a versatile platform capable of addressing a wide range of neurological and movement disorders. This enables rapid development and expansion of AI therapeutics across multiple indications.
Fasikl is the only company able to record human peripheral nerve activity at single fiber resolution while delivering stimulation. These breakthroughs enable real-time neural decoding and the creation of next-generation, AI-driven neuromodulation therapies.
We are pioneering a nerve-computer interface tested in human amputees, enabling natural, high-degree-of-freedom control of robotic limbs. Users simply think, and the hand responds – restoring intuitive, voluntary movement.
At Fasikl, innovation is driven by a singular goal: improving lives. We prioritize efficacy, safety, and patient experience in everything we build – restoring not just motor function, but dignity and independence.
Our long-term vision is to lead the future of body-AI communication. Backed by over 20 years of foundational research, Fasikl is building a world where AI integrates with the human nervous system to transform how we treat disease.
Please contact Dr. Zhi Yang, CEO of Fasikl.
Copyright © 2025 Fasikl Inc. | Privacy Notice | Notice of Privacy Practices | Terms of Use | Accessibility Statement
